IMMX Quote, Financials, Valuation and Earnings

Agenus, Inc. has a net margin of -- compared to Immix Biopharma, Inc.'s net margin of -116.82%. Immix Biopharma, Inc.'s return on equity of -220.98% beat Agenus, Inc.'s return on equity of --.

Immix Biopharma, Inc. has a consensus price target of $11.07, signalling upside risk potential of 29.28%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 285.42%. Given that Agenus, Inc. has higher upside potential than Immix Biopharma, Inc., analysts believe Agenus, Inc. is more attractive than Immix Biopharma, Inc..

Immix Biopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.567, suggesting its more volatile than the S&P 500 by 56.664%.

Immix Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immix Biopharma, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.

Immix Biopharma, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Immix Biopharma, Inc.'s net income of -$7.6M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Immix Biopharma, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immix Biopharma, Inc. is -- versus 0.81x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Immix Biopharma, Inc.'s net margin of 16.99%. Immix Biopharma, Inc.'s return on equity of -220.98% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Immix Biopharma, Inc. has a consensus price target of $11.07, signalling upside risk potential of 29.28%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 39.63%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Immix Biopharma, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Immix Biopharma, Inc..

Immix Biopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.

Immix Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immix Biopharma, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Immix Biopharma, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Immix Biopharma, Inc.'s net income of -$7.6M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Immix Biopharma, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 145.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immix Biopharma, Inc. is -- versus 11.76x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Arrowhead Pharmaceuticals, Inc. has a net margin of -- compared to Immix Biopharma, Inc.'s net margin of 10.7%. Immix Biopharma, Inc.'s return on equity of -220.98% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 50.21%.

Immix Biopharma, Inc. has a consensus price target of $11.07, signalling upside risk potential of 29.28%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $81.36 which suggests that it could grow by 24.98%. Given that Immix Biopharma, Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Immix Biopharma, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..

Immix Biopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.227, suggesting its more volatile than the S&P 500 by 22.681%.

Immix Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immix Biopharma, Inc. pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Immix Biopharma, Inc. quarterly revenues are --, which are smaller than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $264M. Immix Biopharma, Inc.'s net income of -$7.6M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $28.2M. Notably, Immix Biopharma, Inc.'s price-to-earnings ratio is -- while Arrowhead Pharmaceuticals, Inc.'s PE ratio is 42.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immix Biopharma, Inc. is -- versus 8.20x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Savara, Inc. has a net margin of -- compared to Immix Biopharma, Inc.'s net margin of --. Immix Biopharma, Inc.'s return on equity of -220.98% beat Savara, Inc.'s return on equity of -78.83%.

Immix Biopharma, Inc. has a consensus price target of $11.07, signalling upside risk potential of 29.28%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 92.39%. Given that Savara, Inc. has higher upside potential than Immix Biopharma, Inc., analysts believe Savara, Inc. is more attractive than Immix Biopharma, Inc..

Immix Biopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.931%.

Immix Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immix Biopharma, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.

Immix Biopharma, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Immix Biopharma, Inc.'s net income of -$7.6M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Immix Biopharma, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immix Biopharma, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.